HEALTH PROFESSIONAL · SOURCE READING

Immunotherapy (PD-1 inhibitors)

Source: Skin Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Squamous Cell Carcinoma of the Skin / Treatment of Metastatic Squamous Cell Carcinoma (or Advanced Disease Untreatable by Local Modalities)

Two PD-1 inhibitors, cemiplimab and pembrolizumab, have been approved by the FDA as systemic therapy for recurrent or metastatic SCC not amenable to curative surgery or radiation therapy (cemiplimab, pembrolizumab) and locally advanced SCC not amenable to curative surgery (cemiplimab).

Continue within this section

Cemiplimab →Pembrolizumab →

Preserved source evidence · Not medical advice